Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Recommendations for respiratory syncytial virus surveillance at the national level

AC. Teirlinck, EK. Broberg, A. Stuwitz Berg, H. Campbell, RM. Reeves, A. Carnahan, B. Lina, G. Pakarna, H. Bøås, H. Nohynek, HD. Emborg, H. Nair, J. Reiche, JA. Oliva, J. O'Gorman, J. Paget, K. Szymanski, K. Danis, M. Socan, M. Gijon, M. Rapp, M....

. 2021 ; 58 (3) : . [pub] 20211001

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003571

Grantová podpora
001 World Health Organization - International

Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infections and hospitalisations among young children and is globally responsible for many deaths in young children, especially in infants aged <6 months. Furthermore, RSV is a common cause of severe respiratory disease and hospitalisation among older adults. The development of new candidate vaccines and monoclonal antibodies highlights the need for reliable surveillance of RSV. In the European Union (EU), no up-to-date general recommendations on RSV surveillance are currently available. Based on outcomes of a workshop with 29 European experts in the field of RSV virology, epidemiology and public health, we provide recommendations for developing a feasible and sustainable national surveillance strategy for RSV that will enable harmonisation and data comparison at the European level. We discuss three surveillance components: active sentinel community surveillance, active sentinel hospital surveillance and passive laboratory surveillance, using the EU acute respiratory infection and World Health Organization (WHO) extended severe acute respiratory infection case definitions. Furthermore, we recommend the use of quantitative reverse transcriptase PCR-based assays as the standard detection method for RSV and virus genetic characterisation, if possible, to monitor genetic evolution. These guidelines provide a basis for good quality, feasible and affordable surveillance of RSV. Harmonisation of surveillance standards at the European and global level will contribute to the wider availability of national level RSV surveillance data for regional and global analysis, and for estimation of RSV burden and the impact of future immunisation programmes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003571
003      
CZ-PrNML
005      
20220127150107.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1183/13993003.03766-2020 $2 doi
035    __
$a (PubMed)33888523
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Teirlinck, Anne C $u National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Bilthoven, The Netherlands anne.teirlinck@rivm.nl
245    10
$a Recommendations for respiratory syncytial virus surveillance at the national level / $c AC. Teirlinck, EK. Broberg, A. Stuwitz Berg, H. Campbell, RM. Reeves, A. Carnahan, B. Lina, G. Pakarna, H. Bøås, H. Nohynek, HD. Emborg, H. Nair, J. Reiche, JA. Oliva, J. O'Gorman, J. Paget, K. Szymanski, K. Danis, M. Socan, M. Gijon, M. Rapp, M. Havlíčková, R. Trebbien, R. Guiomar, SS. Hirve, S. Buda, S. van der Werf, A. Meijer, TK. Fischer
520    9_
$a Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infections and hospitalisations among young children and is globally responsible for many deaths in young children, especially in infants aged <6 months. Furthermore, RSV is a common cause of severe respiratory disease and hospitalisation among older adults. The development of new candidate vaccines and monoclonal antibodies highlights the need for reliable surveillance of RSV. In the European Union (EU), no up-to-date general recommendations on RSV surveillance are currently available. Based on outcomes of a workshop with 29 European experts in the field of RSV virology, epidemiology and public health, we provide recommendations for developing a feasible and sustainable national surveillance strategy for RSV that will enable harmonisation and data comparison at the European level. We discuss three surveillance components: active sentinel community surveillance, active sentinel hospital surveillance and passive laboratory surveillance, using the EU acute respiratory infection and World Health Organization (WHO) extended severe acute respiratory infection case definitions. Furthermore, we recommend the use of quantitative reverse transcriptase PCR-based assays as the standard detection method for RSV and virus genetic characterisation, if possible, to monitor genetic evolution. These guidelines provide a basis for good quality, feasible and affordable surveillance of RSV. Harmonisation of surveillance standards at the European and global level will contribute to the wider availability of national level RSV surveillance data for regional and global analysis, and for estimation of RSV burden and the impact of future immunisation programmes.
650    _2
$a senioři $7 D000368
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a hospitalizace $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    12
$a infekce respiračními syncytiálními viry $x diagnóza $x epidemiologie $x prevence a kontrola $7 D018357
650    12
$a lidský respirační syncytiální virus $7 D018113
650    12
$a infekce dýchací soustavy $x diagnóza $x epidemiologie $7 D012141
650    _2
$a sentinelová surveillance $7 D018571
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Broberg, Eeva K $u European Centre for Disease Prevention and Control, Stockholm, Sweden
700    1_
$a Stuwitz Berg, Are $u Norwegian Institute of Public Health, Oslo, Norway
700    1_
$a Campbell, Harry $u Usher Institute, University of Edinburgh, Edinburgh, UK
700    1_
$a Reeves, Rachel M $u Usher Institute, University of Edinburgh, Edinburgh, UK
700    1_
$a Carnahan, AnnaSara $u Public Health Agency Stockholm, Solna, Sweden
700    1_
$a Lina, Bruno $u HCL & University of Lyon, Lyon, France
700    1_
$a Pakarna, Gatis $u Riga East University Hospital, Riga, Latvia
700    1_
$a Bøås, Håkon $u Norwegian Institute of Public Health, Oslo, Norway
700    1_
$a Nohynek, Hanna $u Finnish National Institute for Health and Welfare, Helsinki, Finland
700    1_
$a Emborg, Hanne-Dorthe $u Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Nair, Harish $u Usher Institute, University of Edinburgh, Edinburgh, UK
700    1_
$a Reiche, Janine $u Robert Koch Institute, Berlin, Germany
700    1_
$a Oliva, Jesus Angel $u Instituto de Salud Carlos III Madrid, CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
700    1_
$a O'Gorman, Joanne $u Health Protection Surveillance Centre, Dublin, Ireland
700    1_
$a Paget, John $u Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands
700    1_
$a Szymanski, Karol $u National Institute of Public Health, Warsaw, Poland
700    1_
$a Danis, Kostas $u Santé Publique France (SpFrance), Saint-Maurice, France
700    1_
$a Socan, Maja $u Public Health Institute, Ljubljana, Slovenia
700    1_
$a Gijon, Manuel $u Foundazione PENTA Onlus, Padova, Italy
700    1_
$a Rapp, Marie $u Public Health Agency Stockholm, Solna, Sweden
700    1_
$a Havlíčková, Martina $u National Institute of Public Health, Praha, Czech Republic
700    1_
$a Trebbien, Ramona $u Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Guiomar, Raquel $u National Institute of Health, Lisbon, Portugal
700    1_
$a Hirve, Siddhivinayak S $u World Health Organization, Geneva, Switzerland
700    1_
$a Buda, Silke $u Robert Koch Institute, Berlin, Germany
700    1_
$a van der Werf, Sylvie $u Institut Pasteur, UMR 3569 CNRS, University of Paris, Paris, France
700    1_
$a Meijer, Adam $u National Institute for Public Health and the Environment (RIVM) - Centre for Infectious Disease Control, Bilthoven, The Netherlands
700    1_
$a Fischer, Thea K $u Statens Serum Institut, Copenhagen, Denmark $u Dept of Clinical Research, Nordsjaellands Hospital, Hilleroed, Denmark $u Dept of Global Health and Infectious Diseases, University of Southern Denmark, Odense, Denmark
773    0_
$w MED00001660 $t The European respiratory journal $x 1399-3003 $g Roč. 58, č. 3 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33888523 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150103 $b ABA008
999    __
$a ok $b bmc $g 1751128 $s 1154720
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 58 $c 3 $e 20211001 $i 1399-3003 $m The European respiratory journal $n Eur Respir J $x MED00001660
GRA    __
$a 001 $p World Health Organization $2 International
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace